Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.38 |
| ▸ | MVD | P53602 | 3/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29225919 | 0.97 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL3823202 | 0.97 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL1274886 | 0.87 | — | — | |
| SCHEMBL333910 | 0.87 | — | — | |
| Triphosphate SCHEMBL18714 | 0.87 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.87 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL29692 | 0.85 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL5049158 | 0.84 | FDPS (0.56) | FDPSBLMTDP1BTN3A1 | |
| Triphosphate SCHEMBL25284822 | 0.83 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL897837 | 0.83 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590683-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-07-30 | — | — | EP | claimed |
| EP-4561631-A2 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| CN-118516431-A | Novel method for producing oligonucleotides | 葛兰素史克知识产权开发有限公司 | 2024-08-20 | — | — | CN | claimed |
| US-20240209406-A1 | ENZYMATIC SYNTHESIS OF NTP AND NQP | CODEXIS, INC. | 2024-06-27 | — | — | US | claimed |
| WO-2024129235-A1 | ENZYMATIC SYNTHESIS OF NTP AND NQP | CODEXIS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| CN-111479923-B | Novel method for producing oligonucleotides | 葛兰素史克知识产权开发有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-05-23 | — | — | US | claimed |
| EP-4370132-A2 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| EP-4367125-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| EP-0914462-A1 | TARGET NUCLEIC ACID SEQUENCE AMPLIFICATION | MOLECULAR BIOLOGY RESOURCES, INC. (US) | 1999-05-12 | — | — | EP | claimed |
| EP-0866796-A1 | IMPROVEMENTS IN OR RELATING TO MUTAGENESIS OF NUCLEIC ACIDS | MEDICAL RESEARCH COUNCIL (GB) | 1998-09-30 | — | — | EP | claimed |
| WO-1998013523-A1 | METHOD OF SEQUENCING DNA | PYROSEQUENCING AB (SE) | 1998-04-02 | — | — | WO | claimed |
| WO-1997035026-A1 | TARGET NUCLEIC ACID SEQUENCE AMPLIFICATION | MOLECULAR BIOLOGY RESOURCES, INC. (US) | 1997-09-25 | — | — | WO | claimed |
| WO-1997011083-A1 | IMPROVEMENTS IN OR RELATING TO MUTAGENESIS OF NUCLEIC ACIDS | MEDICAL RESEARCH COUNCIL (GB) | 1997-03-27 | — | — | WO | claimed |
| US-5525471-A | INCORPORATION OF NUCLEOSIDE ANALOGS TO PREVENT SUBSEQUENT EXONUCLEASE ATTACK | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | claimed |
| US-4728730-A | Synthesis of nucleoside thiophosphoanhydrides | WISCONSIN ALUMINI RESEARCH FOUNDATION (US) | 1988-03-01 | — | — | US | claimed |
| EP-0183800-A1 | METHOD OF DETECTION NUCLEIC ACID SEQUENCES | RODLAND, Karin D. (US) | 1986-06-11 | — | — | EP | claimed |
| WO-1985005642-A1 | METHOD OF DETECTION NUCLEIC ACID SEQUENCES | RODLAND KARIN D | 1985-12-19 | — | — | WO | claimed |
| US-4521509-A | Method for degrading DNA | RESEARCH CORPORATION (US) | 1985-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, NUDT1, NT5C3B | FDPS 18/4885BLM 1756/4885TDP1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.